Medline, Inc. Total Operating Expenses increased by 13.2% to $1.42B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.2%, from $1.25B to $1.42B. This is a positive signal — lower values indicate better performance for this metric.
Rising expenses without a corresponding rise in revenue can indicate operational bloat or aggressive expansion efforts.
The sum of all costs required to run the business that are not directly tied to production, including R&D and SG&A. It r...
Investors compare this to revenue to assess the 'operating leverage' of a business model.
total_operating_expenses| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.16B | $1.16B | $1.16B | $1.16B | $1.21B | $1.21B | $1.21B | $1.21B | $1.25B | $1.42B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +4.2% | +0.0% | +0.0% | +0.0% | +3.8% | +13.2% |
| YoY Change | — | — | — | — | +4.2% | +4.2% | +4.2% | +4.2% | +3.8% | +13.2% |